<< Back to News

New FDA Approval for Empliciti

On November 6, 2018 Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.

Click Here to read the entire Press Release

Click Here to read the Prescribing Information